Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors

Haematologica. 2023 Jan 19. doi: 10.3324/haematol.2022.282148. Online ahead of print.

Authors

Gregory W Roloff¹, Frank Wen¹, Aubrianna Ramsland¹, Andrew S Artz², Satyajit Kosuri¹, Wendy Stock¹, Olatoyosi Odenike¹, Richard A Larson¹, Hongtao Liu¹, Lucy A Godley¹, Michael J Thirman¹, Anand A Patel¹, Christopher K Daugherty¹, Adam S DuVall¹, Mariam T Nawas¹, Emily Dworkin¹, Geoffrey D Wool³, Sandeep Gurbuxani³, Carrie Fitzpatrick³, Jeremy P Segal³, Peng Wang³, Michael W Drazer⁴

Affiliations

¹ Section of Hematology/Oncology, The University of Chicago.
² Division of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte CA.
³ Department of Pathology, The University of Chicago.
⁴ Section of Hematology/Oncology, The University of Chicago. mdrazer@medicine.bsd.uchicago.edu.

PMID: 36655425
DOI: 10.3324/haematol.2022.282148

Abstract

Not available.